Private Advisor Group’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.77M | Sell |
8,433
-261
| -3% | -$122K | 0.02% | 761 |
|
|
2025
Q4 | $3.94M | Buy |
8,694
+1,330
| +18% | +$573K | 0.02% | 722 |
|
|
2025
Q3 | $2.88M | Buy |
7,364
+160
| +2% | +$66.9K | 0.01% | 854 |
|
|
2025
Q2 | $3.21M | Sell |
7,204
-248
| -3% | -$114K | 0.02% | 746 |
|
|
2025
Q1 | $3.61M | Buy |
7,452
+242
| +3% | +$113K | 0.02% | 649 |
|
|
2024
Q4 | $2.9M | Sell |
7,210
-34
| -0.5% | -$15.8K | 0.02% | 723 |
|
|
2024
Q3 | $3.37M | Sell |
7,244
-977
| -12% | -$469K | 0.02% | 657 |
|
|
2024
Q2 | $3.85M | Buy |
8,221
+243
| +3% | +$105K | 0.03% | 585 |
|
|
2024
Q1 | $3.33M | Sell |
7,978
-2,343
| -23% | -$990K | 0.02% | 603 |
|
|
2023
Q4 | $4.2M | Buy |
10,321
+500
| +5% | +$185K | 0.03% | 493 |
|
|
2023
Q3 | $3.42M | Sell |
9,821
-2,894
| -23% | -$1.01M | 0.03% | 520 |
|
|
2023
Q2 | $4.48M | Buy |
12,715
+6,591
| +108% | +$2.22M | 0.04% | 438 |
|
|
2023
Q1 | $1.93M | Sell |
6,124
-1,193
| -16% | -$358K | 0.02% | 699 |
|
|
2022
Q4 | $570K | Buy |
7,317
+1,517
| +26% | +$462K | 0.03% | 531 |
|
|
2022
Q3 | $1.68M | Sell |
5,800
-25,971
| -82% | -$7.47M | 0.02% | 699 |
|
|
2022
Q2 | $8.95M | Buy |
31,771
+2,155
| +7% | +$577K | 0.08% | 243 |
|
|
2022
Q1 | $7.73M | Sell |
29,616
-1,363
| -4% | -$323K | 0.06% | 305 |
|
|
2021
Q4 | $6.8M | Sell |
30,979
-903
| -3% | -$176K | 0.05% | 356 |
|
|
2021
Q3 | $5.78M | Buy |
31,882
+3,955
| +14% | +$772K | 0.04% | 460 |
|
|
2021
Q2 | $5.63M | Buy |
27,927
+16,382
| +142% | +$3.43M | 0.05% | 369 |
|
|
2021
Q1 | $2.48M | Buy |
11,545
+1,389
| +14% | +$305K | 0.02% | 622 |
|
|
2020
Q4 | $2.4M | Buy |
10,156
+1,162
| +13% | +$267K | 0.03% | 603 |
|
|
2020
Q3 | $2.51M | Buy |
8,994
+1,799
| +25% | +$496K | 0.03% | 490 |
|
|
2020
Q2 | $2.09M | Buy |
7,195
+2,244
| +45% | +$608K | 0.03% | 521 |
|
|
2020
Q1 | $1.18M | Buy |
4,951
+262
| +6% | +$60.1K | 0.02% | 603 |
|
|
2019
Q4 | $1.03M | Sell |
4,689
-920
| -16% | -$186K | 0.02% | 743 |
|
|
2019
Q3 | $996K | Buy |
5,609
+1,798
| +47% | +$318K | 0.02% | 799 |
|
|
2019
Q2 | $691K | Sell |
3,811
-778
| -17% | -$136K | 0.01% | 898 |
|
|
2019
Q1 | $845K | Buy |
4,589
+481
| +12% | +$88.8K | 0.02% | 749 |
|
|
2018
Q4 | $681K | Sell |
4,108
-1,054
| -20% | -$183K | 0.02% | 718 |
|
|
2018
Q3 | $995K | Buy |
5,162
+1,680
| +48% | +$299K | 0.02% | 686 |
|
|
2018
Q2 | $591K | Buy |
3,482
+1,036
| +42% | +$161K | 0.01% | 683 |
|
|
2018
Q1 | $399K | Sell |
2,446
-1,539
| -39% | -$251K | 0.02% | 763 |
|
|
2017
Q4 | $621K | Sell |
3,985
-1,948
| -33% | -$288K | 0.03% | 564 |
|
|
2017
Q3 | $921K | Buy |
5,933
+476
| +9% | +$71.6K | 0.02% | 601 |
|
|
2017
Q2 | $702K | Buy |
5,457
+129
| +2% | +$15.5K | 0.02% | 687 |
|
|
2017
Q1 | $607K | Buy |
5,328
+94
| +2% | +$8.28K | 0.02% | 728 |
|
|
2016
Q4 | $428K | Sell |
5,234
-1
| -0% | -$81 | 0.01% | 792 |
|
|
2016
Q3 | $453K | Sell |
5,235
-659
| -11% | -$62.3K | 0.02% | 693 |
|
|
2016
Q2 | $528K | Buy |
5,894
+929
| +19% | +$80.3K | 0.02% | 612 |
|
|
2016
Q1 | $377K | Sell |
4,965
-484
| -9% | -$43.8K | 0.02% | 677 |
|
|
2015
Q4 | $686K | Buy |
5,449
+363
| +7% | +$43.8K | 0.03% | 496 |
|
|
2015
Q3 | $530K | Sell |
5,086
-1,166
| -19% | -$150K | 0.03% | 553 |
|
|
2015
Q2 | $772K | Buy |
6,252
+1,091
| +21% | +$137K | 0.04% | 463 |
|
|
2015
Q1 | $609K | Buy |
5,161
+3,250
| +170% | +$389K | 0.04% | 490 |
|
|
2014
Q4 | $227K | Buy |
+1,911
| New | +$215K | 0.01% | 822 |
|
Other funds holding VRTX
VCM
VPM
Private Advisor Group's VRTX Position: Q1 2026 in Review
Private Advisor Group reduced its Vertex Pharmaceuticals (VRTX) stake by 3% in Q1 2026, selling an estimated $122K and leaving 8,433 shares worth $3.77M. The position accounts for 0.02% of the portfolio, ranked #761.
Private Advisor Group first reported a position in VRTX in Q4 2014 and has held it in 46 quarters since. The position peaked at $8.95M in Q2 2022. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Private Advisor Group held 8,433 shares of Vertex Pharmaceuticals worth $3.77M as of Q1 2026.
- Private Advisor Group sold 261 Vertex Pharmaceuticals shares in Q1 2026, an estimated $122K.
- Vertex Pharmaceuticals made up 0.02% of Private Advisor Group's portfolio in Q1 2026, its #761 holding.
- Private Advisor Group first reported a position in Vertex Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
- Private Advisor Group's Vertex Pharmaceuticals position peaked at $8.95M in Q2 2022.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Private Advisor Group's 13F filing for Q1 2026, filed 27 Apr 2026.